EUCTR2007-001697-84-DK
Active, Not Recruiting
Phase 1
Pharmacological intervention of blood flow disturbances in diabetic retinal disease - Retinal blood flow and diabetes
Department of Ophthalmology, Aarhus University Hospital0 sites80 target enrollmentJune 12, 2007
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetic retinal disease
- Sponsor
- Department of Ophthalmology, Aarhus University Hospital
- Enrollment
- 80
- Status
- Active, Not Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diabetes type 1
- •Blood pressure \< 135/85,
- •HbA1c \< 9%
- •Moderate diabetic retinal disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Persons treated with antiglaucoma medicine
- •Persons with known eye disease, except diabetic retinal disease
- •Persons with cardio\-vascular disease or blood pressure \>140/90\.
- •Pregnant women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Improvement of blood pressure and blood flow by intake of test articleJPRN-UMIN000033336Japan clinical trial association54
Not Yet Recruiting
N/A
EFFECTIVENESS OF BFRT ON PATIENTS WITH KNEE OSTEOARTHRITIS GRADE 2Health Condition 1: M171- Unilateral primary osteoarthritisof kneeCTRI/2023/05/052454ONE
Completed
N/A
A study for improving effects on the blood flow and the skin by carbonate cosmeticsHealthy adultsJPRN-UMIN000025658Kao Corporation40
Recruiting
Phase 2
Effects of pharmacological treatments in heart failure with preserved ejection fractioHeart failure with preserved ejection fractionJPRN-jRCT1031220336Obokata Masaru125
Active, Not Recruiting
N/A
Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension(Shorttitle: SIPHT)Double-blind, randomized, prospective Phase III-b study for 6 months with adjusting doses of simvastatin (40/80 mg daily) or placebo followed by an open-label period with a final dose of simvastatin 80 mg daily for another 6 months - SIPHTModified NYHA class II or III patients with Pulmonary Hypertension (PH), ICD: 416.9MedDRA version: 8.1Level: LLTClassification code 10020787Term: Hypertension pulmonaryEUCTR2005-004863-41-DEDept. of Internal Medicine II, University Hospital Giessen40